Oocyte Cryopreservation in Transgender and Gender-Diverse Individuals With or Without Prior Testosterone Use

Obstet Gynecol. 2024 Dec 1;144(6):e121-e124. doi: 10.1097/AOG.0000000000005749. Epub 2024 Sep 26.

Abstract

To evaluate oocyte cryopreservation among transgender and gender-diverse adolescents and young adults with or without prior testosterone exposure, we performed a retrospective cohort study of all patients younger than age 35 years referred for oocyte cryopreservation through our formal fertility-preservation program from 2014 to 2023. The number of patients referred and pursuing fertility preservation increased over time. Among the 93 patients referred, 37 pursued oocyte cryopreservation (31 testosterone-naïve and six testosterone-exposed). Among the latter, neither length of time on testosterone before presentation nor duration off testosterone before retrieval (minimum 2 months) were associated with the number of mature oocytes frozen. When comparing testosterone-naïve with testosterone-exposed individuals, there was no difference in number of oocytes retrieved (median 28 vs 32, P =0.43) or mature oocytes frozen (21 vs 21, P =0.95).

MeSH terms

  • Adolescent
  • Adult
  • Cryopreservation*
  • Female
  • Fertility Preservation* / methods
  • Humans
  • Male
  • Oocyte Retrieval
  • Oocytes* / drug effects
  • Retrospective Studies
  • Testosterone* / therapeutic use
  • Transgender Persons*
  • Young Adult

Substances

  • Testosterone